DP
HRTX icon

DSAM Partners’s Heron Therapeutics HRTX Stock Holding History

DSAM Partners’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-283,415
Closed -$4.59M – 47
2021
Q1 		$4.59M Sell
283,415
-67,743
-19% -$1.21M 0.85% 32
2020
Q4 		$7.43M Buy
351,158
+89,852
+34% +$1.56M 0.87% 39
2020
Q3 		$3.87M Buy
+261,306
New +$4.08M 0.67% 31

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DSAM Partners's HRTX Position: Q2 2021 in Review

DSAM Partners sold out of Heron Therapeutics (HRTX) in Q2 2021, closing a stake of 283,415 shares — an estimated $4.59M sold.

DSAM Partners first reported a position in HRTX in Q3 2020 and held it in 3 quarters. The position peaked at $7.43M in Q4 2020. 189 funds tracked by Wall St. Rank hold HRTX as of Q2 2021.

  • DSAM Partners reported no remaining Heron Therapeutics position as of Q2 2021 after selling out during the quarter.
  • DSAM Partners sold 283,415 Heron Therapeutics shares in Q2 2021, an estimated $4.59M.
  • DSAM Partners first reported a position in Heron Therapeutics in Q3 2020 and held it in 3 quarters.
  • DSAM Partners's Heron Therapeutics position peaked at $7.43M in Q4 2020.
  • 189 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2021.

Based on DSAM Partners's 13F filing for Q2 2021, filed 16 Aug 2021.